Therapeutic modulation of cutaneous autoimmunity by regulatory T cells
Department of Dermatology, University of Münster, D-48149 Münster and 1Interdisciplinary Clinical Research Center (IZKF), Münster, Germany.
Correspondence to: Stefan Beissert, MD, Department of Dermatology, University of Münster, Von-Esmarch-Strasse 58, D-48149 Münster/Germany. E-mail: beisser{at}uni-muenster.de
Cutaneous autoimmunity is characterized by the presence of autoantibodies and/or autoreactive T cells. Several mechanisms have been developed to avoid loss of immunotolerance to self such as activation-induced cell death, deletion, ignorance and active suppression of autoreactivity. Regulatory (‘suppressor’) T cells play a pivotal role in inhibiting the activation and function of effector T cells. CD4+CD25+ T cells constitute a subset of regulatory T cells, which have been shown to suppress the development of organ-specific autoimmunity in mice. Recent understanding in the generation and function of human regulatory T cells indicates that these cells are involved in the appearance of inflammatory as well as bullous autoimmune dermatosis. These findings suggest that modulation of regulatory T cell numbers or function might be a promising therapeutic alternative for the treatment of such disorders. In the following, recent strategies aimed at inducing antigen-specific or non-specific regulatory T cells for the immunotherapy of ongoing cutaneous autoimmunity are presented and discussed. Hopefully, pursuing these strategies in the future will result in the initiation of randomized clinical studies analysing the usefulness of regulatory T cells for human skin diseases in great detail.